GOLM1 Promotes Pulmonary Fibrosis through Upregulation of NEAT1.
| Title: | GOLM1 Promotes Pulmonary Fibrosis through Upregulation of NEAT1. |
|---|---|
| Authors: | Wang, Yani, Hu, Danjing, Wan, Linyan, Yang, Shuhui, Liu, Song, Wang, Zixi, Li, Jie, Li, Jia, Zheng, Zhoude, Cheng, Chongsheng, Wang, Yanan, Wang, Hanghang, Tian, Xinlun, Chen, Wenhui, Li, Shanqing, Zhang, Ji, Zha, Xiaojun, Chen, Jingyu, Zhang, Hongbing, Xu, Kai-Feng |
| Source: | American Journal of Respiratory Cell & Molecular Biology; Mar2024, Vol. 70 Issue 3, p178-192, 15p |
| Subject Terms: | PULMONARY fibrosis, IDIOPATHIC pulmonary fibrosis, MEMBRANE proteins, GENE expression, EXTRACELLULAR matrix |
| Abstract: | Idiopathic pulmonary fibrosis (IPF) is a lethal progressive disease with elusive molecular mechanisms and limited therapeutic options. Aberrant activation of fibroblasts is a central hallmark of lung fibrosis. Here, we report that Golgi membrane protein 1 (GOLM1, also known as GP73 or GOLPH2) was increased in the lungs of patients with pulmonary fibrosis and mice with bleomycin (BLM)–induced pulmonary fibrosis. Loss of GOLM1 inhibited proliferation, differentiation, and extracellular matrix deposition of fibroblasts, whereas overexpression of GOLM1 exerted the opposite effects. Similarly, worsening pulmonary fibrosis after BLM treatment was observed in GOLM1–knock-in mice, whereas BLM-treated Golm1-knockout mice exhibited alleviated pulmonary fibrosis and collagen deposition. Furthermore, we identified long noncoding RNA NEAT1 downstream of GOLM1 as a potential mediator of pulmonary fibrosis through increased GOLM1 expression. Depletion of NEAT1 inhibited fibroblast proliferation and extracellular matrix production and reversed the profibrotic effects of GOLM1 overexpression. Additionally, we identified KLF4 as a downstream mediator of GOLM1 signaling to NEAT1. Our findings suggest that GOLM1 plays a pivotal role in promoting pulmonary fibrosis through the GOLM1–KLF4–NEAT1 signaling axis. Targeting GOLM1 and its downstream pathways may represent a novel therapeutic strategy for treating pulmonary fibrosis. [ABSTRACT FROM AUTHOR] |
| Copyright of American Journal of Respiratory Cell & Molecular Biology is the property of American Thoracic Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Complementary Index |
Be the first to leave a comment!